X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (1279) 1279
Publication (179) 179
Book Review (19) 19
Book Chapter (9) 9
Book / eBook (8) 8
Newspaper Article (5) 5
Dissertation (2) 2
Conference Proceeding (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (836) 836
humans (821) 821
animals (468) 468
oncology (386) 386
cancer (335) 335
male (302) 302
dentistry, oral surgery & medicine (277) 277
mice (271) 271
female (258) 258
administration, oral (229) 229
signal transduction (222) 222
apoptosis (210) 210
kinases (205) 205
dentistry (196) 196
expression (196) 196
cell line, tumor (195) 195
proteins (178) 178
activation (177) 177
analysis (166) 166
phosphorylation (161) 161
oral mek inhibitor (153) 153
squamous cell carcinoma (151) 151
tumors (151) 151
middle aged (150) 150
pharmacology & pharmacy (144) 144
article (139) 139
adult (138) 138
oral cancer (134) 134
research (134) 134
gene expression (128) 128
cell biology (127) 127
signal transduction - drug effects (125) 125
digestive, oral, and skin physiology (124) 124
care and treatment (120) 120
aged (119) 119
metastasis (119) 119
cells, cultured (118) 118
research article (115) 115
health aspects (113) 113
mutation (113) 113
cell proliferation (112) 112
cell proliferation - drug effects (111) 111
rats (105) 105
in-vitro (104) 104
medicine (104) 104
angiogenesis (100) 100
inflammation (99) 99
rodents (96) 96
multidisciplinary sciences (95) 95
biochemistry & molecular biology (93) 93
growth (92) 92
chemotherapy (91) 91
dose-response relationship, drug (91) 91
extracellular signal-regulated kinase (91) 91
carcinoma, squamous cell - pathology (89) 89
melanoma (88) 88
antineoplastic agents - pharmacology (87) 87
oral squamous cell carcinoma (87) 87
antineoplastic agents - therapeutic use (86) 86
genetic aspects (86) 86
map kinase signaling system - drug effects (85) 85
apoptosis - drug effects (84) 84
immunohistochemistry (84) 84
cells (83) 83
blotting, western (82) 82
proliferation (82) 82
nf-kappa-b (81) 81
mouth neoplasms - pathology (80) 80
science (80) 80
map kinase (79) 79
inhibition (77) 77
squamous-cell carcinoma (76) 76
neoplasms - drug therapy (75) 75
development and progression (74) 74
enzyme inhibitors - pharmacology (74) 74
pathway (74) 74
cell cycle (73) 73
pathology (72) 72
treatment outcome (71) 71
gene-expression (70) 70
carcinoma, squamous cell - metabolism (69) 69
protein kinase inhibitors - pharmacology (69) 69
disease models, animal (68) 68
cancer therapies (67) 67
carcinoma (67) 67
medicine & public health (67) 67
antineoplastic agents - administration & dosage (66) 66
breast-cancer (66) 66
cell line (66) 66
head (66) 66
physiological aspects (66) 66
protein kinases (66) 66
cell growth (65) 65
carcinoma, squamous cell - genetics (64) 64
studies (64) 64
stem cells (63) 63
up-regulation (63) 63
biology (62) 62
mouth neoplasms - metabolism (62) 62
mice, nude (60) 60
more...
Library Location Library Location
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Lancet Oncology, The, ISSN 1470-2045, 2012, Volume 13, Issue 8, pp. 782 - 789
Summary Background MEK is a member of the MAPK signalling cascade that is commonly activated in melanoma. Direct inhibition of MEK blocks cell proliferation... 
Hematology, Oncology and Palliative Medicine | SURVIVAL | BRAF | ONCOLOGY | RAF | SOMATIC MUTATIONS | PROGRESSION | Skin Neoplasms - drug therapy | United States | Humans | Middle Aged | Melanoma - enzymology | Male | Antineoplastic Agents - administration & dosage | Protein Kinase Inhibitors - adverse effects | Molecular Targeted Therapy | Uveal Neoplasms - enzymology | Young Adult | Pyridones - administration & dosage | Skin Neoplasms - enzymology | Time Factors | Antineoplastic Agents - adverse effects | DNA Mutational Analysis | Melanoma - genetics | Skin Neoplasms - mortality | Adult | Female | Skin Neoplasms - pathology | MAP Kinase Kinase 1 - antagonists & inhibitors | Uveal Neoplasms - genetics | Uveal Neoplasms - pathology | Drug Administration Schedule | Administration, Oral | Pyrimidinones - adverse effects | Kaplan-Meier Estimate | MAP Kinase Kinase 1 - metabolism | Treatment Outcome | MAP Kinase Kinase 2 - metabolism | Melanoma - pathology | Uveal Neoplasms - drug therapy | Disease-Free Survival | Protein Kinase Inhibitors - administration & dosage | MAP Kinase Kinase 2 - antagonists & inhibitors | Proto-Oncogene Proteins B-raf - genetics | Melanoma - drug therapy | Skin Neoplasms - genetics | Uveal Neoplasms - mortality | Aged | Pyrimidinones - administration & dosage | Mutation | Pyridones - adverse effects | Melanoma - mortality | Prevention | Care and treatment | Melanoma | Cancer | Index Medicus
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2012, Volume 13, Issue 8, pp. 773 - 781
Journal Article
Journal Article
Journal Article
British Journal of Cancer, ISSN 0007-0920, 05/2017, Volume 116, Issue 11, pp. 1402 - 1407
Journal Article
Journal Article
PLoS ONE, ISSN 1932-6203, 06/2014, Volume 9, Issue 6, p. e100880
Tumor cells upregulate many cell signaling pathways, with AKT being one of the key kinases to be activated in a variety of malignancies. GSK2110183 and... 
BREAST-CANCER | APOPTOSIS | ACTIVATING MUTATION | PHOSPHORYLATION | PROTEIN-KINASE | MULTIDISCIPLINARY SCIENCES | PLECKSTRIN HOMOLOGY DOMAIN | RICTOR | INDUCTION | EGFR | Ribosomal Protein S6 Kinases - metabolism | Pyrazoles - chemical synthesis | Antineoplastic Agents - chemical synthesis | Humans | Gene Expression Regulation, Neoplastic | Phosphatidylinositol 3-Kinases - metabolism | Phosphatidylinositol 3-Kinases - antagonists & inhibitors | Proto-Oncogene Proteins c-akt - genetics | Pancreatic Neoplasms - drug therapy | PTEN Phosphohydrolase - antagonists & inhibitors | Female | Antineoplastic Agents - pharmacology | Drug Evaluation, Preclinical | MAP Kinase Kinase Kinases - antagonists & inhibitors | Proto-Oncogene Proteins c-akt - metabolism | Pyrazoles - pharmacology | PTEN Phosphohydrolase - genetics | Protein Kinase Inhibitors - chemical synthesis | Signal Transduction | Administration, Oral | MAP Kinase Kinase Kinases - genetics | Pancreatic Neoplasms - pathology | Pancreatic Neoplasms - enzymology | PTEN Phosphohydrolase - metabolism | Pancreatic Neoplasms - genetics | MAP Kinase Kinase Kinases - metabolism | Mice, SCID | Drug Synergism | Phosphatidylinositol 3-Kinases - genetics | Xenograft Model Antitumor Assays | Animals | Tumor Burden - drug effects | Cell Line, Tumor | Diamines - pharmacology | Mice | Protein Kinase Inhibitors - pharmacology | Blood Glucose - metabolism | Diamines - chemical synthesis | Ribosomal Protein S6 Kinases - antagonists & inhibitors | Ribosomal Protein S6 Kinases - genetics | Proto-Oncogene Proteins c-akt - antagonists & inhibitors | Cellular signal transduction | Glucose | Phosphotransferases | Dextrose | Tumors | Biotechnology | Phosphorylation | Animal models | Leukemia | Homeostasis | Oncology | AKT protein | Kinases | K-Ras protein | Anticancer properties | Feedback | Polyethylene glycol | Inhibition | Enzymes | Tumor cells | MAP kinase | Breast cancer | Bioavailability | Substrates | 1-Phosphatidylinositol 3-kinase | Studies | Signaling | Inhibitors | Pancreatic cancer | Cell lines | Mutation | Laboratory animals | ATP | PTEN protein | Cancer | Apoptosis
Journal Article
CLINICAL CANCER RESEARCH, ISSN 1078-0432, 01/2014, Volume 20, Issue 2, pp. 490 - 498
Journal Article
Journal Article
Clinical Cancer Research, ISSN 1078-0432, 08/2014, Volume 20, Issue 16, pp. 4251 - 4261
Journal Article
Drug Metabolism and Disposition, ISSN 0090-9556, 01/2016, Volume 44, Issue 1, pp. 28 - 39
Journal Article
Journal Article
British Journal of Clinical Pharmacology, ISSN 0306-5251, 01/2018, Volume 84, Issue 1, pp. 52 - 63
Journal Article